New Publication Shows PROSTOX™ ultra Test Delivers Significant Health System Cost Savings and Quality-of-Life Gains for Prostate Cancer Patients Undergoing Radiation Therapy MiraDx, a molecular ...
MiraDx Announces the Commercial Availability of PROSTOX™ ultra for Prediction of Risk of Late Genitourinary Toxicity in Prostate Cancer Patients Considering Radiation Therapy MiraDx, a molecular ...
PROSTOX test predicts urinary side effects in prostate cancer patients using microRNAs to assess genetic risk factors. The test identifies high-risk patients, who are 10 to 12 times more likely to ...
The test also can distinguish men at risk for different types of side effects WEDNESDAY, April 16, 2025 (HealthDay News) -- Radiation therapy is commonly used to treat prostate cancer, but it can ...
Investigators at the UCLA Health Jonsson Comprehensive Cancer Center have validated a test that can accurately predict which patients with prostate cancer are at higher risk of developing long-lasting ...
LOS ANGELES, December 18, 2025--(BUSINESS WIRE)--MiraDx, a molecular diagnostics company focused on germline genetic testing to personalize cancer treatment, announced a new analysis has been ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results